Investors Menu

News Details

Eagle Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Financial Results on March 7, 2022

2/24/2022

WOODCLIFF LAKE, N.J., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2021 fourth quarter and full year financial results on Monday, March 7, 2022, before the market opens.

Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will host a conference call to discuss the results as follows:

Date Monday, March 7, 2022
Time 8:30 a.m. ET
Toll free (U.S.) 866-831-8713
International 203-518-9822
   
Webcast (live and replay) www.eagleus.com, under the “Investor Relations” section

A replay of the conference call will be available for one week after the call's completion by dialing 800-839-0866 (US) or 402-220-0662 (International) and entering conference call ID EGRXQ421. The webcast will be archived for 30 days at the aforementioned URL.

About Eagle Pharmaceuticals, Inc. 
Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include vasopressin, PEMFEXY™, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), and its oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. Additional information is available on Eagle’s website at www.eagleus.com.

Contact:
Investor Relations for Eagle Pharmaceuticals, Inc:
Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com


Primary Logo

Source: Eagle Pharmaceuticals, Inc.

Change % Volume Data as of 04/15/2022 1:08 AM EDT Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Contact

In-Site
Communications, Inc.
Lisa M. Wilson,
212-452-2793

For all other media inquiries, please contact us.